Mohammad Keykhaei, MD, MPH (@MKeykhaeiMD) header
Mohammad Keykhaei, MD, MPH (@MKeykhaeiMD) profile picture

PGY-2 IM Resident @DOM_UCLA| Former Postdoc @HopkinsHeart| #JACCCardioOnc SoMe Consultant| Editorial Board @BMC_GPH, @FrontCVMedicine|🫀🏊🏼‍♂️✈️🎹📚

Los Angeles
Joined May 2026
1/🚨Excited to share our new study in @JACCJournals #JACCHeartFailure “National Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction” shorturl.at/tnQZD My sincere gratitude goes to Dr. @gcfmd for his exceptional mentorship and guidance, and to our outstanding team for their collaboration and support: @ATSandhu @HsuePriscilla @SJGreene_md @boback @MKIttlesonMD @MattRamsisMD @uclaimchiefs @DOM_UCLA @uclaCVfellows @UCLAHealth @UCLAHealthNews #HFrEF #GDMT
19
7
42
2,845
Mohammad Keykhaei, MD, MPH retweeted
Needs a full-force response Implement quadruple GDMT (ARNI/ACEi/ARB, BB, MRA, SGLT2i) for EVERY eligible patient in EVERY setting, whether inpatient, clinic or telehealth 🚀 Start early, titrate fast, close the gap ❤️ #GDMT #HeartFailure #Cardiology
2
3
63
Mohammad Keykhaei, MD, MPH retweeted
🩺 Intensive vs standard BP: 9 RCTs, 65K patients 
📉 Every HR <1 (0.73–0.90); pooled HR 0.82, 95% CI 0.78-0.87 
🧮 Heterogeneity of treatment effect? None: I²=0% 
🎯 Lower SBP ➡️ better outcomes in HTN, T2D and stroke Implement!
1
8
21
1,086
Mohammad Keykhaei, MD, MPH retweeted
How does the immune system contribute to doxorubicin-induced #Cardiotoxicity?🫀 This review highlights the role of innate & adaptive immune responses in DOX-induced cardiac injury: 📍DOX-induced cardiomyocyte stress triggers DAMP release, activating TLR9 & NLRP3 inflammasome signaling, leading to proinflammatory cytokine release, immune cell recruitment, endothelial activation & fibroblast reprogramming 📍Innate immunity: Neutrophils contribute to myocardial injury through ROS, proteolytic enzymes & NETs. 📍Adaptive immunity: Cytotoxic CD8+ T cells & B cells amplify cardiac injury, whereas CD4+ regulatory T cells & iNKT cells exert opposing cardioprotective effects 📍From reversible injury to irreversible remodeling: Sustained & dysregulated immune activation promotes myocardial damage and tissue remodeling, influenced by age, comorbidities, genetic factors, medications & prior immune history Read more in #JACCCardioOnc:
🔗 jacc.org/doi/epdf/10.1016/j.… #CardioOncology #CardioImmunology
1
4
7
358
Mohammad Keykhaei, MD, MPH retweeted
I invite you to enjoy a recent podcast that I recorded that discussed mechanisms for CVD on diabetes. Mins 1:48-3:00, and then minute 30:00 to the end, although I would encourage listening to the whole thing! diabetesbio.libsyn.com/insul…
2
22
953
Mohammad Keykhaei, MD, MPH retweeted
Incredible interview with three of our ⭐️ @uclaimchiefs residents @qicong_sheng @MKeykhaeiMD @Tylermorad discussing our recent State-of-the-Art Review on outpatient management of ICI myocarditis. @DOM_UCLA @uclaCVfellows @datsunian
🚨 New JACC: CardioOncology State-of-the-Art Review: How do we manage the aftermath of ICI myocarditis once patients leave the hospital? 📺 Watch our video interview: youtube.com/watch?v=h_P84RuZ… with the authors @Tylermorad and @MKeykhaeiMD as they break down ICI myocarditis outpatient surveillance, biomarker interpretation, steroid tapering, & ICI rechallenge. #cardioonc @JACCJournals
1
3
15
754
🎙️Check out our recent interview highlighting our JACC:CardioOncology review on the management & surveillance of ICI myocarditis! 🙏 Grateful to @JACCJournals and @qicong_sheng for the wonderful interview, and to @datsunian and @A_SteinMerlob for their invaluable mentorship & support! 📖 Article Link: doi.org/10.1016/j.jaccao.202… @Tylermorad @DOM_UCLA @uclaCVfellows @uclaimchiefs @UCLAHealth
An additional plug for these @DOM_UCLA @uclaimchiefs ALL of them are @UCLAHealth fantastic residents interested in cards and doing so much already for the #cardioonc field!!! @A_SteinMerlob @IntMedAbel @kewatson @gcfmd @ICOSociety @JACCJournals
5
30
695
Mohammad Keykhaei, MD, MPH retweeted
🚨 New JACC: CardioOncology State-of-the-Art Review: How do we manage the aftermath of ICI myocarditis once patients leave the hospital? 📺 Watch our video interview: youtube.com/watch?v=h_P84RuZ… with the authors @Tylermorad and @MKeykhaeiMD as they break down ICI myocarditis outpatient surveillance, biomarker interpretation, steroid tapering, & ICI rechallenge. #cardioonc @JACCJournals
6
2
16
2,058
Mohammad Keykhaei, MD, MPH retweeted
Not every patient receiving HER2-targeted therapy has the same cardiovascular risk. Join us this Wednesday on Nov 18 to explore emerging evidence on risk stratification and cardiac surveillance and what it could mean for more individualized monitoring. Register: acc-org.zoom.us/meeting/regi… #CardioOnc #JACCCardioOnc
5
5
211
Mohammad Keykhaei, MD, MPH retweeted
🏆 Huge congratulations to @RamonaE_91 on winning the #BestPosterAward at the #InternationalSocietyForAppliedCardiovascularBiology meeting, Thx to @joshdhutch & #ISACB2026 organizers for a fantastic meeting @FIU NorthMiami campus. @umiamimedicine #Proudmentor #cardioimmunology
1
2
1
20
953
Mohammad Keykhaei, MD, MPH retweeted
Join leading #CardioOnc experts to explore emerging evidence on CV risk and more individualized approaches to monitoring during HER2-targeted therapy. Reserve Your Spot Today: bit.ly/3VmV6CU @Abdelcards, @anita_deswal, @drtarsh #JACCCardioOnc
3
1
15
2,940
🫀 Can we better individualize cardiac surveillance during HER2-targeted therapy? Join the @JACCJournals #JACCCardioOnc Journal Club on Nov 18 at 11 AM ET to explore emerging evidence on cardiovascular risk stratification. Register: acc-org.zoom.us/meeting/regi…
2
20
456
Mohammad Keykhaei, MD, MPH retweeted
Two great first author papers by @SarnoffCardio @UCLA Victoria Yuan this week! First, AI can accurately and rapidly adjudicate diastolic dysfunction, including reanalyzing historical studies with both 2016 and 2025 @ASE360 diastology guidelines to identify discordance and differences in outcomes in HFpEF! Second, AI echo detection of cardiac amyloid would have picked up ATTR-CM in over 40% of cases prior to clinical diagnosis. Retrospective look-back of echos in patients eventually diagnosed with ATTR-CM finds many early signs even years prior to diagnosis! onlinejcf.com/article/S1071-… onlinejcf.com/article/S1071-…
14
51
3,739
❤️ Lp(a) is more than a coronary risk factor. This US analysis of 1.1 million people reveals distinct first CVD presentations across age, sex and ethnicity, highlighting its pan-vascular impact. #Lp(a) #CardioPrevention #EJPC ⤵️ow.ly/g5eU5105GTZ @escardio @AboyansV @SilCastelletti @PeroneFrancesco @PTBuketAkinci @SMosteoru @TimKambic
6
35
1
97
8,067
Mohammad Keykhaei, MD, MPH retweeted
In the US, all 4 are readily available with generic priced options and fully covered by all drug plans with no or minimal copayment Further, any individual with valid prescriptions can self pay for all 4 meds at a price of 79 cents a day total by @costplusdrugs
4
2
4
264
Mohammad Keykhaei, MD, MPH retweeted
✅ 4 drug classes cut HFrEF deaths: ARNI, BB, MRA, SGLT2i 
❌ 30 others with great rationale failed in Phase 3 RCTs 
🇺🇸 Only 18% get all 4 → ~114K US deaths preventable/yr 
🎯 Implement GDMT with the same intensity we test new drugs 
#HFrEF #CardioTwitter @HFSA @ACCinTouch
3
10
19
1,379
Mohammad Keykhaei, MD, MPH retweeted
In case you missed it, here are all late breaking clinical trial results from #ScientificSessions26.
3
51
142
9,843
Mohammad Keykhaei, MD, MPH retweeted
Join the @JACCJournals JACC: CardioOncology Journal Club on Wednesday, 11/18 at 11AM EST for a clinically focused discussion on cardiovascular risk during HER2-targeted therapy 🎗️🫀 Register Here: tinyurl.com/yebn84f3
7
15
630
Mohammad Keykhaei, MD, MPH retweeted
A farewell 📸 w/ #cardioonc bosses of #AHA26 @AHAScience 🔥 array of sessions by @DrGuptaD w/ @ICOSociety prez @Dr_Mike_Fradley Our village will always continue growing to address the 🌊 of cancer survivorship that will need CVD care Spreading awareness & 🔬 will never stop
3
4
1
46
1,392